Key Highlights

• Sonic Healthcare reported results for the year ended 30 June 2026 on 20 August 2026.

• Revenue rose 13% to A$10.87 billion, while underlying EBITDA rose 11% to A$1.933 billion.

• The company said it met its FY26 underlying EBITDA guidance.

• Total dividends for the year were A$1.08 per share, one cent higher than the prior year.

What does Sonic Healthcare (ASX:SHL)'s FY26 result say about whether acquisition-led growth can turn into more encouraging earnings? The pathology and radiology operator delivered a year of double-digit revenue growth after integrating LADR in Germany, but its FY27 outlook points to a slower, more operational phase, with a United States review and several regulatory pressures in Europe.

The central development: growth meets integration

Sonic Healthcare reported results for the year ended 30 June 2026 on 20 August 2026. Revenue rose 13% to A$10.87 billion, while underlying EBITDA rose 11% to A$1.933 billion. Organic revenue growth was 5%.

The company said it met its FY26 underlying EBITDA guidance. Total dividends for the year were A$1.08 per share, one cent higher than the prior year.

The result matters because a large share of the growth came from acquisitions rather than existing operations. Management is now focused on extracting synergies, restructuring weaker operations and modernising systems.

What Sonic does and how it earns revenue

Sonic is one of the world's larger medical diagnostics groups. Its main Business is laboratory medicine, or pathology, where it processes samples referred by doctors, hospitals and health systems. It also operates radiology in Australia and provides some other medical services.

Revenue comes from several markets, each with its own funding model. In Australia, income comes from Medicare rebates and private billing. In Germany and Switzerland it depends on statutory and private fee schedules. In the United Kingdom, the NHS is a major customer. In the United States, payment comes from insurers and other payers. The United States contributed about 19% of group revenue, according to one results.

This spread diversifies the business, but fee decisions by governments and insurers constantly influence earnings.

Operating performance by region

Australia grew organically by 5%, with specialist referrals up 7%. Management said margins held despite fee changes. Germany's revenue rose 43%, reflecting LADR, with organic growth of 5%. More than 40% of expected LADR synergies were captured in the first year, with the rest anticipated over the following two years.

Switzerland grew 4% organically in constant currency, accelerating to 6% in the second half, with encouraging Margin expansion. The United Kingdom's revenue rose 17%, driven by the first full year of the Hertfordshire and West Essex NHS contract.

The United States was the weak spot. Statutory revenue fell 3% and organic growth was flat in constant currency. Management put underlying organic growth at about 2% after adjusting for a lost Alabama payer contract and an anatomical pathology restructuring. Advanced diagnostics, however, grew about 16% organically.

The United States review

Sonic has begun a comprehensive operating review of its US business. Actions so far include rationalising nine anatomical pathology practices, closing some laboratories, simplifying test portfolios and cutting about 10% of central corporate headcount late in FY26.

Management expects initiatives to add A$25 million to A$30 million to FY27 earnings. On the call, it said it was considering further steps and had not ruled out other options, but that its focus remained on the review. That is a statement of possibilities, not an announced decision, and the outcome is unknown.

FY27 guidance and margin pressures

For FY27, Sonic guided to constant-currency EBITDA of A$1.95 billion to A$2.03 billion, excluding roughly A$30 million of back-office technology transformation costs. The midpoint is about 3% above FY26 underlying EBITDA, on our own calculation. The CFO estimated a currency headwind of roughly A$40 million to A$50 million at the EBITDA line at prevailing exchange rates.

Several specific pressures were flagged:

• Switzerland: fee cuts on ten high-volume tests took effect on 1 July 2026 and are expected to reduce FY27 revenue by about 20 million Swiss francs, around 3% of Swiss revenue. Synergies are expected to offset part of this.

• United Kingdom: FY27 margins are expected to be flat to slightly down. Delays to the Watford hub transfer mean target margins on the NHS contract are now expected around the second half of FY28.

• Germany: proposed changes to the GOÄ private fee schedule could affect around one-third of German revenue, although management considers implementation before 2028 unlikely.

• Australia: Fair Work wage decisions are estimated to add about A$4 million for phlebotomists and A$2.8 million for health professionals in FY27.

The guidance excludes property gains, future acquisitions, future regulatory changes and potential US PAMA fee cuts.

Balance sheet and Capital management

Net interest-bearing Debt rose to about A$3.07 billion from A$2.82 billion, mainly reflecting the LADR and Ciro acquisitions, partly offset by the A$445 million sale and leaseback of the Brisbane Bowen Hills hub laboratory to Charter Hall. Sonic reported debt cover of about 2.2 times EBITDA against a covenant ceiling of 3.5 times, and roughly A$1.6 billion of cash and undrawn funding at 30 June 2026.

A new EUR245 million bank Facility is intended to refinance US private Placement debt maturing in November 2026.

Sector conditions and competitive position

Diagnostics Demand is supported by ageing populations, chronic disease management and growth in specialised testing. Scale helps with procurement, automation and data capability, and Sonic competes with large operators such as Healius and Australian Clinical Labs in Australia, and with large laboratory groups in Europe and the United States. Competitive intensity and government fee-setting, rather than volume, are usually the main constraints.

Index status

Sonic is a large, long-standing constituent of the S&P/ASX 200, and it was not named in the September 2026 quarterly rebalance changes, effective 21 September 2026.

Risks and what to watch

Key uncertainties include delivery on the US review, execution of the LADR and Swiss integrations, European fee reform, UK contract timing, foreign exchange movements and refinancing costs. The first-half FY27 result will offer the next evidence on guidance.